3-Aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 17, 2006, Pages 4620-4623

  Rivkin, Alexey ^a   Kim, Yoona R ^a   Goulet, Mark T ^a   Bays, Nathan ^a   Hill, Armetta D ^a   Kariv, Ilona ^a   Krauss, Stefan ^a   Ginanni, Nicole ^a   Strack, Peter R ^a   Kohl, Nancy E ^a   Chung, Christine C ^a   Varnerin, Jeffrey P ^a   Goudreau, Paul N ^a   Chang, Amy ^a   Tota, Michael R ^a   Munoz, Benito ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Apoptosis; Cancer; Fatty acid synthase

Indexed keywords

FATTY ACID SYNTHASE INHIBITOR; QUINOLINOL DERIVATIVE;

ARTICLE; BINDING SITE; DRUG ACTIVITY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IC 50; MICROWAVE RADIATION; NONHUMAN; POLYMERIZATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ENZYME INHIBITORS; FATTY ACID SYNTHETASE COMPLEX; HUMANS; HYDROXYQUINOLINES; MALONATES; MICROWAVES; MOLECULAR STRUCTURE; QUINOLINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33746206311     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.06.014     Document Type: Article

References (16)

1. Kuhajda F.P., Jenner K., Wood F.D., Hennigar R.A., Jacobs L.B., Dick J.D., and Pasternack G.R. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 6379
2. Zhou W., Simpson J.P., McFadden J.M., Townsend C.A., Medghalchi S.M., Vadlamudi A., Pinn M.L., Ronnett G.V., and Kuhajda F.P. Cancer Res. 63 (2003) 7330
3. Knowles L.M., Axelrod F., Browne C.D., and Smith J.W.A. J. Biol. Chem. 279 (2004) 30540
4. Pizer E.S., Thupari J., Han W.F., Pinn M.L., Chrest F.J., Frehywot G.L., Townsend C.A., and Kuhajda F.P. Cancer Res. 60 (2000) 213
5. Kuhajda F.P., Pizer E., Li J.N., Mani N.S., Frehywot G.L., and Townsend C.A. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 3450
6. De Schrijver E., Brusselmans K., Heyns W., Verhoeven G., and Swinnen J.V. Cancer Res. 63 (2003) 3799
7. Pizer E.S., Lax S.F., Kuhajda D.P., Pasternack G.R., and Kurman R.J. Cancer 83 (1998) 528
8. Rashid A., Pizer E.S., Moga M., Milgraum L.Z., Zahurak M., Pasternack G.R., Kuhajda F.P., and Hamilton S.R. Am. J. Pathol. 150 (1997) 201
9. Milgraum L.Z., Witters L.A., Pasternack G.R., and Kuhajda F.P. Clin. Cancer Res. 3 (1997) 2115
10. McFadden J.M., Medghalchi S.M., Thupari J.N., Pinn M.L., Vadlamudi A., Miller K.I., Kuhajda F.P., and Townsend C.A. J. Med. Chem. 48 (2005) 946
11. Asturias F.J., Chadick J.Z., Cheung I.K., Stark H., Witkowski A., Joshi A.K., and Smith S. Nat. Struct. Mol. Biol. 12 (2005) 225
12. Maier T., Jenni S., and Ban N. Science 311 (2006) 1258
13. Rivkin A., and Adams B. Tetrahedron Lett. 47 (2006) 2395
14. DeVita R.J., Hollings D.D., Goulet M.T., Wyvratt M.J., Fisher M.H., Lo J.L., Yang Y.T., Cheng K., and Smith R.G. Bioorg. Med. Chem. Lett. 9 (1999) 2615
15. DeVita R.J., Goulet M.T., Wyvratt M.J., Fisher M.H., Lo J.L., Yang Y.T., Cheng K., and Smith R.G. Bioorg. Med. Chem. Lett. 9 (1999) 2621
16. In vitro enzymatic activity of FAS was determined by monitoring the production of free coenzyme A (CoA-SH) from malonyl- and acetyl-CoA during the FAS enzymatic reaction. CoA-SH levels were determined using the thiol-reactive dye 7-diethylamino-3-(4-maleimidophenyl)-4-methylcoumarin (CPM). Unreacted CPM is nonfluorescent, whereas the CPM-CoA adduct shows a peak fluorescence emission at 475 nM after excitation at 380 nM.